RESUMEN
Objectives: Enuresis is common among children with sickle cell disease (SCD). Many risk factors have been postulated, but its relation to hyposthenuria is debatable. This study aimed to determine the prevalence of enuresis in children with SCD in Basrah, Iraq, and to examine its relation with hyposthenuria. Methods: A cross-sectional epidemiological study was performed on children with SCD who met the inclusion criteria at the Basrah Center for Hereditary Blood Diseases from December 2020 to May 2021. A questionnaire was used to collect relevant data. Blood samples were tested for haemoglobin genotype, certain blood indices and serum haemoglobin. Urine was tested for albumin and creatinine, and the specific gravity was measured using urine dipsticks. The relationships between enuresis and various sociodemographic and clinical variables were assessed. Binary logistic regression analysis was done to examine the independent risk factors of enuresis. Results: A total of 161 out of 200 eligible children were included in this study (response rate: 80.5%). The majority of participants (60.9%) were males. The mean age of the participants was 10.9 ± 2.9 years. Enuresis was reported in 50 (31.1%) patients. The independent risk factors for enuresis included family history of enuresis (adjusted odds ratio [OR] = 5.94, 95% confidence interval [CI]: 2.54-13.89; P <0.001), hyposthenuria (OR = 3.76, 95% CI: 1.25-11.30; P = 0.018) and sleep disorders (OR = 2.90, 95% CI: 1.19-7.06; P = 0.019. Conclusion: Enuresis is common among children with SCD in Basrah, Iraq. Hyposthenuria was significantly associated with enuresis. Family history of enuresis and sleep disorders were also found to be significantly related to enuresis.
Asunto(s)
Anemia de Células Falciformes , Enuresis Nocturna , Orina , Adolescente , Niño , Femenino , Humanos , Masculino , Anemia de Células Falciformes/epidemiología , Anemia de Células Falciformes/orina , Estudios Transversales , Irak/epidemiología , Enuresis Nocturna/epidemiología , Enuresis Nocturna/orina , Prevalencia , Factores de Riesgo , Gravedad Específica , Encuestas y Cuestionarios , Orina/químicaRESUMEN
Proteinuria is a manifestation of sickle cell anemia (SCA)-related renal disease and is a risk factor of renal impairment. Angiotensin-converting enzyme (ACE) inhibitors have benefits, but their role in SCA remains undefined. This study aimed to assess the role of lisinopril, an ACE inhibitor, in reducing proteinuria in SCA patients. Thirty-five patients older than 15 years with known SCA (HbSS or HbS-ß0) and a 24-h urinary protein level of 150 mg or more participated in this study. Urine was collected over 24 h to quantify proteinuria. The patients had a mean age of 28.5 ± 6.98 years. The median 24-h urinary protein before treatment was 0.3006 g and that after treatment was 0.150 g (P = 0.01). After a median follow-up of 38 months, 24-h urinary protein decreased in 27 (77%) patients and normalized in 18 (52%) patients. Urinary protein increased in 2 (6%) patients and remained stable (no change) in 6 (17%) patients. There was no significant difference in blood pressure (BP) before and after treatment. The average dose of lisinopril was 5 mg. Twenty patients were still on lisinopril at last follow-up. The reasons for stopping lisinopril included normalization of protein, noncompliance, adverse effects, and pregnancy. Lisinopril effectively reduced proteinuria in SCA patients, without significantly reducing BP. Only a few patients developed adverse effects, including coughing, dizziness, and diarrhea. It is unclear how long lisinopril should be continued and whether it can be stopped in patients with normalized urinary protein.
Asunto(s)
Anemia de Células Falciformes , Inhibidores de la Enzima Convertidora de Angiotensina , Lisinopril , Proteinuria , Humanos , Lisinopril/uso terapéutico , Proteinuria/tratamiento farmacológico , Proteinuria/orina , Femenino , Masculino , Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Inhibidores de la Enzima Convertidora de Angiotensina/efectos adversos , Anemia de Células Falciformes/complicaciones , Anemia de Células Falciformes/tratamiento farmacológico , Anemia de Células Falciformes/orina , Adulto , Adulto Joven , Resultado del Tratamiento , Factores de Tiempo , Presión Sanguínea/efectos de los fármacos , AdolescenteRESUMEN
INTRODUCTION: Sickle cell anaemia is characterized by defective haemoglobin synthesis and is associated with both endocrine and metabolic alterations. The effects of this clinical condition on kidney function are multifactorial and often begin early in childhood. This study aims to assess renal function in children with sickle cell anaemia using urine albumin:creatinine ratio (ACR) and urine human neutrophil gelatinase-associated lipocalin (NGAL). METHODS: This case-control study was conducted on 200 children aged 5-15 years in 2 tertiary hospitals in South West Nigeria: 150 were of haemoglobin S genotype and 50 were of haemoglobin A genotype. Serum urea, creatinine, urine albumin, and NGAL were assayed by known standard methods. eGFR, urine ACR, and urine NGAL/creatinine ratio (urine NCR) were calculated. RESULTS: The weight, height, BMI, systolic blood pressure, plasma urea, plasma creatinine, and spot urine creatinine of the HbS genotype children were significantly lower compared to that of the HbA genotype children. The eGFR, spot urine albumin, and urine ACR were significantly higher in the HbS group compared to the HbA group. There was no significant difference in the spot urine NGAL and urine NCR between the 2 groups, though both were higher in the HbS group compared to the HbA group. CONCLUSIONS: Kidney injury probably starts early in childhood in sickle cell individuals as indicated by the higher urine ACR detected in them. We infer that urine NGAL and uNCR are not sensitive markers of kidney disease especially in young sickle cell individuals possibly because of the hyperfiltration present at this age.
Asunto(s)
Albuminuria , Anemia de Células Falciformes/sangre , Anemia de Células Falciformes/orina , Creatinina , Riñón/metabolismo , Lipocalina 2/orina , Urea/sangre , Adolescente , Albúminas , Biomarcadores/sangre , Biomarcadores/orina , Estudios de Casos y Controles , Niño , Preescolar , Creatinina/sangre , Creatinina/orina , Femenino , Tasa de Filtración Glomerular , Humanos , Masculino , NigeriaRESUMEN
Aim: The aim of this study was to compare novel kidney injury biomarkers in sickle cell anemia (SCA) children with and without albuminuria or glomerular hyperfiltration. Materials & methods: A total of 358 Brazilian children with SCA were studied. Fifteen kidney injury biomarkers in urine were measured. Albuminuria was defined as urine albumin/creatinine ratio >100 mg/g. Glomerular hyperfiltration was defined as estimated glomerular filtration rate ≥140 ml/min/1.73 m2. Results: After adjustment for age, sex and modifying therapies in use, EGF and collagen IV urinary levels were associated with albuminuria. Renin and clusterin levels were associated with hyperfiltration. Conclusion: Levels of novel kidney injury biomarkers were associated with albuminuria and hyperfiltration in Brazilian children with SCA, suggesting concomitant structural and functional abnormalities.
Asunto(s)
Albuminuria/orina , Anemia de Células Falciformes/orina , Biomarcadores/orina , Enfermedades Renales/orina , Adolescente , Albuminuria/complicaciones , Albuminuria/diagnóstico , Anemia de Células Falciformes/complicaciones , Brasil , Niño , Estudios de Cohortes , Estudios Transversales , Tasa de Filtración Glomerular , Humanos , Riñón/patología , Riñón/fisiopatología , Enfermedades Renales/complicaciones , Enfermedades Renales/diagnóstico , Pruebas de Función Renal/métodos , MasculinoRESUMEN
BACKGROUND: There is no reliable marker for detecting early renal disease in early children with sickle cell disease (SCD). Estimation of glomerular filtration rate (eGFR) as derived from the height/plasma creatinine formula is dependent on the accuracy of the creatinine analytical method used. The aim of this study was to evaluate different equations for eGFR. METHODS: Children aged 5-16 years recruited. mGFR was obtained using plasma disappearance of Inutest/Iohexol, serum creatinine (SCr) was measured either by standard laboratory method or by tandem mass spectrometry (MSMS). Estimated GFR was then calculated either by "Bedside Schwartz method" or by the full-age spectrum (FAS) equation. FINDINGS: A total of 79 patients (mean age 9.8 ± 4.0 years). A revised eGFR constant was calculated for Schwartz equation from the slope of the plot of height/plasma creatinine versus mGFR. Mean values for mGFR (132.7 ± 32.1 ml/min/1.73m2) and eGFR methods compared: eGFR from standard SCr was significantly higher (144.2 ± 37.3 ml/min/1.73m2, p = 0.008). The MSMS eGFR showed the lowest SD (SD = 27.5), while both FAS eGFR and FAS-height eGFR showed the highest correlation coefficient (r = 0.67). INTERPRETATION: eGFR calculation based on height and SCr determined with MSMS traceable creatinine is more reliable than Schwartz formula using jaffe/enzymatic methods in SCD children.
Asunto(s)
Anemia de Células Falciformes/fisiopatología , Tasa de Filtración Glomerular , Riñón/fisiopatología , Adolescente , Anemia de Células Falciformes/sangre , Anemia de Células Falciformes/orina , Niño , Preescolar , Femenino , Humanos , Pruebas de Función Renal , Masculino , Proyectos Piloto , Reproducibilidad de los ResultadosRESUMEN
Sickle cell nephropathy (SCN) develops via altered hemodynamics and acute kidney injury, but conventional screening tests remain normal until advanced stages. Early diagnostic biomarkers are needed so that preventive measures can be taken. This study evaluates the role of neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker of SCN in steady state and vaso-occlusive crisis (VOC). In this case-control study, 74 sickle cell disease (SCD) patients (37 in steady state and 37 in VOC) and 53 control subjects had hematological and biochemical measurements including plasma and urine NGAL. Univariate and logistic regression analyses were used to find the associations between variables. The receiver operating characteristic (ROC) curve was used to determine the diagnostic performance characteristics of plasma and urine NGAL for detection of VOC. Plasma and urine NGAL, urine microalbumin:creatinine ratio, and urine protein:creatinine ratio were significantly higher in VOC. Microalbuminuria was present in 17.1% steady state and 32.0% VOC patients. Microalbuminuria showed significant correlations with age, plasma NGAL, WBC, and hemolytic parameters. Area under the ROC curve for plasma NGAL was 0.69 (95%CI = 0.567-0.813; p = 0.006) and 0.86 (95%CI = 0.756-0.954; p < 0.001) for urine NGAL. Urine NGAL cut-off value of 12.0 ng/mL had 95% sensitivity and 65% specificity. These results confirm the presence of nephropathy during VOC and suggest that plasma and urine NGAL would be useful in the identification of SCN. Urine NGAL should be used as the screening biomarker, and patients with VOC and urine NGAL > 12.0 ng/mL should be selected for aggressive management to prevent progression of renal damage.
Asunto(s)
Lesión Renal Aguda/sangre , Anemia de Células Falciformes/sangre , Lipocalina 2/sangre , Lesión Renal Aguda/etiología , Lesión Renal Aguda/orina , Adulto , Anemia de Células Falciformes/complicaciones , Anemia de Células Falciformes/orina , Biomarcadores/sangre , Biomarcadores/orina , Estudios de Casos y Controles , Femenino , Humanos , Lipocalina 2/orina , Masculino , Curva ROCRESUMEN
Kidney iron deposition measured by R2* (magnetic resonance imaging) MRI is posited to result from tubular reabsorption of filtered haemoglobin due to intravascular haemolysis. In chronically transfused sickle cell disease (SCD), R2* is elevated and positively correlated with lactate dehydrogenase (LDH). To account for contributions to renal iron from systemic iron overload, we evaluated kidney R2*, urinary iron and haemolysis markers in 62 non-transfused SCD patients. On multivariate analysis, kidney R2* was associated with urinary iron and LDH (R2 = 0·55, P < 0·0001). Our study confirms that kidney R2* is associated with intravascular haemolysis and raises important questions regarding the role of iron in SCD nephropathy.
Asunto(s)
Anemia de Células Falciformes , Hemólisis , Hierro/orina , Enfermedades Renales , Riñón , Imagen por Resonancia Magnética , Adolescente , Adulto , Anciano , Anemia de Células Falciformes/diagnóstico por imagen , Anemia de Células Falciformes/orina , Biomarcadores/orina , Niño , Femenino , Humanos , Riñón/diagnóstico por imagen , Riñón/metabolismo , Enfermedades Renales/diagnóstico por imagen , Enfermedades Renales/orina , Masculino , Persona de Mediana EdadAsunto(s)
Anemia de Células Falciformes/sangre , Anemia de Células Falciformes/orina , Orosomucoide/metabolismo , Insuficiencia Renal Crónica/sangre , Insuficiencia Renal Crónica/orina , Adolescente , Adulto , Anciano , Biomarcadores/sangre , Biomarcadores/orina , Femenino , Humanos , Masculino , Persona de Mediana Edad , Orosomucoide/orina , Adulto JovenRESUMEN
BACKGROUND: Sickle cell nephropathy (SCN) is a progressive disease that contributes significant morbidity and mortality in sickle cell disease (SCD), yet it remains poorly understood. Hyperuricemia negatively impacts renal function in the non-sickle cell population but is understudied in SCD. METHODS: We performed a cross-sectional analysis of the first 78 pediatric SCD patients enrolled in a cohort study. The mechanism of development of hyperuricemia (defined, serum uric acid (UA) ≥ 5.5 mg/dL) was characterized as a result of either UA overproduction or inefficient renal excretion by the Simkin index and fractional clearance of urate (FCU) equations. Associations between hyperuricemia and albuminuria or estimated glomerular filtration rate (eGFR) were determined by linear regression. RESULTS: The prevalence of hyperuricemia in this young population (mean age 11.6 ± 3.77 years) was 34.2%. Only 1 hyperuricemic participant overproduced UA by Simkin index, while 62.5% were inefficient renal excretors of UA (FCU < 4%). Hyperuricemia was associated with a significant decrease in average eGFR, -27 ml/min/1.73m2 below normouricemia (mean eGFR 151.6 ± 40.32), p = 0.0122. Notably, the previously accepted association between decline of eGFR with age is significantly modified by hyperuricemia stratification, where hyperuricemia explains 44% of the variance in eGFR by age (R2 = 0.44, p = 0.0004) and is nonsignificant in normouricemia (R2 = 0.07, p = 0.0775). CONCLUSION: These findings indicate that hyperuricemia may be associated with early eGFR decline in SCN. This association must be further characterized in prospective cohort studies in SCN, and hyperuricemia must be investigated as a potential therapeutic target for SCN.
Asunto(s)
Albuminuria/epidemiología , Anemia de Células Falciformes/complicaciones , Hiperuricemia/epidemiología , Enfermedades Renales/fisiopatología , Ácido Úrico/metabolismo , Adolescente , Albuminuria/sangre , Albuminuria/fisiopatología , Anemia de Células Falciformes/sangre , Anemia de Células Falciformes/terapia , Anemia de Células Falciformes/orina , Transfusión Sanguínea , Niño , Estudios de Cohortes , Estudios Transversales , Femenino , Tasa de Filtración Glomerular/fisiología , Supresores de la Gota/uso terapéutico , Humanos , Hiperuricemia/sangre , Hiperuricemia/diagnóstico , Hiperuricemia/tratamiento farmacológico , Enfermedades Renales/sangre , Enfermedades Renales/etiología , Enfermedades Renales/orina , Masculino , Prevalencia , Eliminación Renal/fisiología , Factores de Riesgo , Ácido Úrico/sangreRESUMEN
In the present study, the possible activation of cellular immunity in SCD patients was investigated. As immune activation parameters, neopterin concentrations and kynurenine/tryptophan ratio for tryptophan degradation in 35 pediatric patients with sickle cell disease (31 HbSS and 4 HbSß) were determined. Our results have shown that neopterin levels (both urinary and serum) are increased in pediatric patients with sickle cell disease. The increase in neopterin concentration was accompanied by significantly increased biopterin, kynurenine concentration and kynurenine/tryptophan ratio. The mechanism of immune activation and the effects of inflammatory mediators in sickle cell disease are poorly understood, especially in terms of cell-mediated immunity. Further in-vivo and in-vitro studies are required to illuminate the association between neopterin levels and neutrophil activation in sickle cell disease.
Asunto(s)
Anemia de Células Falciformes/sangre , Anemia de Células Falciformes/orina , Neopterin/sangre , Neopterin/orina , Adolescente , Anemia de Células Falciformes/inmunología , Niño , Preescolar , Femenino , Humanos , Inflamación/sangre , Inflamación/inmunología , Inflamación/orina , Masculino , Neopterin/inmunología , Activación Neutrófila , Neutrófilos/inmunología , Neutrófilos/metabolismoRESUMEN
People with sickle cell disease often report severe bone pain with repeated bouts of vaso-occlusive crises, but the extent of skeletal injury incurred during these painful episodes remain unclear. We sought to quantify bone degradation by comparing urinary concentrations of carboxyterminal cross-linked telopeptide of type I collagen (CTX-1), a well-described marker of bone resorption, in a prospective cohort of 52 adults with sickle cell disease enrolled in the Sickle Cell Pain Markers Study. We also questioned if changes in urinary CTX-1 concentrations correlated with changes in hemolysis and inflammatory markers measured both during and after resolution of a painful vaso-occlusive episode. Thirty-one of the 52 adults enrolled in the study had paired urine samples for CTX-1 analysis. Urinary CTX-1, corrected for urine creatinine, significantly decreased from a mean of 3.45⯵g/mmol during vaso-occlusive crises to 2.62⯵g/mmol at recovery (pâ¯=â¯0.01). Thus, increased bone loss appears to correlate with acute vaso-occlusive crises in sickle cell disease. Our finding that urinary CTX-1 can be used to probe bone degradation in sickle cell disease provides an important new tool for diagnosing and monitoring response to therapy for people with sickle cell-related bone loss.
Asunto(s)
Anemia de Células Falciformes/complicaciones , Anemia de Células Falciformes/orina , Biomarcadores , Resorción Ósea/etiología , Resorción Ósea/orina , Colágeno Tipo I/orina , Dolor/etiología , Péptidos/orina , Adulto , Anemia de Células Falciformes/diagnóstico , Femenino , Humanos , MasculinoRESUMEN
Sickle cell disease (SCD) is a hereditary condition characterized by homozygosis of the hemoglobin S (HbS) gene. Marked morbimortality is observed due to chronic hemolysis, endothelial injury, and episodes of vaso-occlusion, which leads to multi-organ damage. Renal impairment is common and may have different presentations, such as deficiency in urinary acidification or concentration, glomerulopathies, proteinuria, and hematuria, frequently resulting in end-stage renal disease (ESRD). Novel biomarkers of renal function, such as kidney injury molecule 1 (KIM-1), and neutrophil gelatinase-associated lipocalin (NGAL) and monocyte chemoattractant protein 1 (MCP-1) are being studied in order to enable early diagnosis of kidney damage in SCD.
Asunto(s)
Anemia de Células Falciformes/orina , Quimiocina CCL2/orina , Receptor Celular 1 del Virus de la Hepatitis A/metabolismo , Fallo Renal Crónico/orina , Riñón/metabolismo , Lipocalina 2/orina , Anemia de Células Falciformes/complicaciones , Biomarcadores/orina , Humanos , Fallo Renal Crónico/etiologíaRESUMEN
Sickle cell disease (SCD)-induced urinary concentration defect has been proposed as caused by impaired ability of the occluded vasa recta due to red blood cell sickling to serve as countercurrent exchangers and renal tubules to absorb water and solutes. However, the exact molecular mechanisms remain largely unknown. The present studies were undertaken to determine the effects of SCD on vasopressin, aquaporin2 (AQP2), urea transporter A1 (UTA1), Na-K-Cl co-transporter 2 (NKCC2), epithelial Na channels (ENaC), aquaporin1 (AQP1), nuclear factor of activated T cells 5 (NFAT5) and Src homology region-2 domain-containing phosphatase-1 (SHP-1), an important regulator of NFAT5, in the Berkeley SCD mouse kidney medulla. Under water repletion, SCD only induced a minor urinary concentration defect associated with increased urinary vasopressin level alone with the well-known effects of vasopressin: protein abundance of AQP2, UTA1 and ENaC-ß and apical targeting of AQP2 as compared with non-SCD. SCD did not significantly affect AQP1 protein level. Water restriction had no further significant effect on SCD urinary vasopressin. NFAT5 is also critical to urinary concentration. Instead, water restriction-activated NFAT5 associated with inhibition of SHP-1 in the SCD mice. Yet, water restriction only elevated urinary osmolality by 28% in these mice as opposed to 104% in non-SCD mice despite similar degree increases of protein abundance of AQP2, NKCC2 and AQP2-S256-P. Water-restriction had no significant effect on protein abundance of ENaC or AQP1 in either strain. In conclusion, under water repletion SCD, only induces a minor defect in urinary concentration because of compensation from the up-regulated vasopressin system. However, under water restriction, SCD mice struggle to concentrate urine despite activating NFAT5. SCD-induced urinary concentration defect appears to be resulted from the poor blood flow in vasa recta rather than the renal tubules' ability to absorb water and solutes.
Asunto(s)
Anemia de Células Falciformes/metabolismo , Acuaporina 2/metabolismo , Canales Epiteliales de Sodio/metabolismo , Riñón/metabolismo , Proteínas de Transporte de Membrana/metabolismo , Miembro 1 de la Familia de Transportadores de Soluto 12/metabolismo , Vasopresinas/metabolismo , Anemia de Células Falciformes/orina , Animales , Acuaporina 1/metabolismo , Acuaporina 2/genética , Canales Epiteliales de Sodio/genética , Femenino , Masculino , Proteínas de Transporte de Membrana/genética , Ratones , Proteína Tirosina Fosfatasa no Receptora Tipo 6/genética , Proteína Tirosina Fosfatasa no Receptora Tipo 6/metabolismo , Miembro 1 de la Familia de Transportadores de Soluto 12/genética , Factores de Transcripción/metabolismo , Regulación hacia Arriba , Equilibrio Hidroelectrolítico , Transportadores de UreaAsunto(s)
Anemia de Células Falciformes/orina , Indicán/orina , Anemia Ferropénica/orina , Animales , Femenino , Humanos , MasculinoRESUMEN
OBJECTIVES: The objective of this study was to assess the prevalence of albuminuria in sickle cell disease patients at the Campus University Hospital of Lome. PATIENTS AND METHOD: Albuminuria was assessed by the urinary albumin-to-creatinine ratio (UACR) in sickle cell disease individuals who attended the outpatient consultation in their steady state. RESULTS: The prevalence of albuminuria was 21% (14/67). Albuminuria was more frequent (32% vs 13%, p=0,054) and occurred earlier (6 years vs 21 years) among the 28 SS/Sß0-thalassemia sickle-cell diseases individuals than the 39 SC ones. Albuminuria was associated with high counts of leukocytes (p=0.033) and neutrophils (p=0.008). It was negatively correlated with hemoglobin level (p=0.032) and positively with LDH (p=0.002), SGOT (p=0.002), leukocytes (p=0.003), neutrophils (p< 0.001) and thrombocytes (p=0.010) counts for all sickle cell patients without statistical confirmation for each sickle cell phenotype apart from neutrophils in SS/Sß0-thalassemia. Defining albuminuria as an UACR greater than 20 mg/g had a specificity of 100% and a sensibility and 90% when the UACR was compared to the 24-hours urines albumin quantification. CONCLUSION: The assessment of albuminuria should begin at age 5 years in SS/Sß0-thalassemia sickle-cell anemia patients and from 20 years old in SC patients by the UACR.
Asunto(s)
Albuminuria/epidemiología , Anemia de Células Falciformes/epidemiología , Adolescente , Adulto , Albuminuria/orina , Anemia de Células Falciformes/complicaciones , Anemia de Células Falciformes/orina , Niño , Preescolar , Estudios Transversales , Femenino , Hospitales Universitarios , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Togo/epidemiología , Adulto JovenAsunto(s)
Anemia de Células Falciformes/tratamiento farmacológico , Antidrepanocíticos/uso terapéutico , Hidroxiurea/uso terapéutico , Adolescente , Anemia de Células Falciformes/sangre , Anemia de Células Falciformes/epidemiología , Anemia de Células Falciformes/orina , Antidrepanocíticos/administración & dosificación , Antidrepanocíticos/efectos adversos , Niño , Preescolar , Femenino , Hospitales de Enseñanza , Humanos , Hidroxiurea/administración & dosificación , Hidroxiurea/efectos adversos , Lactante , Malaui/epidemiología , Masculino , Estudios ProspectivosAsunto(s)
Anemia de Células Falciformes/complicaciones , Ceruloplasmina/orina , Insuficiencia Renal Crónica/diagnóstico , Adulto , Anemia de Células Falciformes/orina , Biomarcadores/orina , Femenino , Humanos , Masculino , Persona de Mediana Edad , Proteómica/métodos , Insuficiencia Renal Crónica/orinaRESUMEN
Chronic pain affects one-half of adults with sickle cell disease (SCD). Despite the prevalence of chronic pain, few studies have been performed to determine the best practices for this patient population. Although the pathophysiology of chronic pain in SCD may be different from other chronic pain syndromes, many of the guidelines outlined in the pain literature and elsewhere are applicable; some were consensus-adopted in the 2014 National Heart, Lung, and Blood Institute SCD Guidelines. Recommended practices, such as controlled substance agreements and monitoring of urine, may seem unnecessary or counterproductive to hematologists. After all, SCD is a severe pain disorder with a clear indication for opioids, and mistrust is already a major issue. The problem, however, is not with a particular disease but with the medicines, leading many US states to pass broad legislation in attempts to curb opioid misuse. These regulations and other key tenets of chronic pain management are not meant to deprive adults with SCD of appropriate therapies, and their implementation into hematology clinics should not affect patient-provider relationships. They simply encourage prudent prescribing practices and discourage misuse, and should be seen as an opportunity to more effectively manage our patient's pain in the safest manner possible. In line with guideline recommendations as well as newer legislation, we present five lessons learned. These lessons form the basis for our model to manage chronic pain in adults with SCD.
Asunto(s)
Anemia de Células Falciformes/terapia , Dolor Crónico/terapia , Manejo del Dolor/métodos , Adulto , Anemia de Células Falciformes/orina , Dolor Crónico/orina , Humanos , Manejo del Dolor/normas , Guías de Práctica Clínica como AsuntoRESUMEN
Sickle cell disease (SCD) is an autosomal recessive disease in which homozygosity for a single point mutation in the gene encoding the ß-globin chain produces hemoglobin S molecules that polymerize within the erythrocyte during deoxygenation; the result is sustained hemolytic anemia and vaso-occlusive events. As patients live to adulthood, the chronic impact of sustained hemolytic anemia and episodic vaso-occlusive episodes leads to progressive end-organ complications. This scenario culminates in the development of 1 or more major cardiovascular complications of SCD for which there are no approved or consensus therapies. These complications include elevated pulmonary artery systolic pressure, pulmonary hypertension, left ventricular diastolic heart disease, dysrhythmia, sudden death, and chronic kidney disease with associated proteinuria, microalbuminuria, and hemoglobinuria. In patients with advancing age, cardiopulmonary organ dysfunction and chronic kidney injury have significant effects on morbidity and premature mortality. Over the last 15 years, a number of tests have been validated in multiple replicate cohort studies that identify patients with SCD at the highest risk of experiencing pulmonary and systemic vasculopathy and death, providing for screening strategies tied to targeted, more aggressive diagnostic and therapeutic interventions.